A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder

Journal of Clinical Psychopharmacology

Volumn 26, Issue 1, 2006, Pages 56-60

  Papakostas, George I ^a   Perlis, Roy H ^a   Scalia, Margaret J ^a   Petersen, Timothy J ^a   Fava, Maurizio ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; DULOXETINE; FLUOXETINE; IMIPRAMINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OXAPROTILINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA EXTRACTION; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL DECISION MAKING; META ANALYSIS; PRIORITY JOURNAL; PUBLICATION; QUANTITATIVE ANALYSIS; RANDOMIZATION; SYSTEMATIC REVIEW;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PLACEBO EFFECT; RANDOMIZED CONTROLLED TRIALS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 31544452090     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jcp.0000195042.62724.76     Document Type: Article

References (42)

1. Quitkin FM, Rabkin JG, Ross D, et al. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry. 1984;41:782-786.
2. Quitkin FM, Rabkin JD, Markowitz JM, et al. Use of pattern analysis to identify true drug response. A replication. Arch Gen Psychiatry. 1987;44:259-264.
3. Dunlop SR, Dornseif BE, Wernicke JF, et al. Pattern analysis shows beneficial effect of fluoxetine treatment in mild depression. Psychopharmacol Bull. 1990;26:173-180.
4. Khan A, Cohen S, Dager S, et al. Onset of response in relation to outcome in depressed outpatients with placebo and imipramine. J Affect Disord. 1989;17:33-38.
5. Stewart JW, Quitkin FM, McGrath PJ, et al. Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo. Arch Gen Psychiatry. 1998;55:334-343.
6. McGrath PJ, Stewart JW, Petkova E, et al. Predictors of relapse during fluoxetine continuation or maintenance treatment of major depression. J Clin Psychiatry. 2000;6:518-524.
7. Nierenberg AA, Quitkin FM, Kremer C, et al. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology. 2004;29:1012-1018.
8. Coryell W, Coppen A, Zeigler VE, et al. Early improvement as a predictor of response to amitriptyline and nortriptyline: a comparison of 2 patient samples. Psychol Med. 1982;12:135-139.
9. Katz MM, Koslow SH, Maas JW, et al. The timing, specificity and clinical prediction of tricyclic drug effects in depression. Psychol Med. 1987;17(2):297-309.
10. Nagayama H, Nagano K, Ikezaki A, et al. Prediction of efficacy of antidepressant by 1-week test therapy in depression. J Affect Disord. 1991;23:213-216.
11. Pollock BG, Perel JM, Kupfer DJ, et al. Early response patterns associated with successful clomipramine treatment. J Clin Psychopharmacol. 1993;13:442-447.
12. Stassen HH, Kuny S, Hell D. The speech analysis approach to determining onset of improvement under antidepressants. Eur Neuropsychopharmacol. 1998;8:303-310.
13. Stassen HH, Angst J, Delini-Stula A. Fluoxetine versus moclobemide: cross-comparison between the time courses of improvement. Pharmacopsychiatry. 1999;32:56-60.
14. Szegedi A, Muller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry. 2003;64:413-420.
15. Nierenberg AA, McLean NE, Alpert JE, et al. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am J Psychiatry. 1995;152:1500-1503.
16. Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J Clin Psychiatry. 2005;66(2):148-158.
17. Papakostas GI, Petersen T, Sklarsky KG, et al. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. 43rd Annual Meeting of the American College of Neuropsychopharmacology; 2004; San Juan, Puerto Rico.
18. Papakostas GI, Petersen T, Denninger JW, et al. Psychosocial functioning during the treatment of major depressive disorder with fluoxetine. J Clin Psychopharmacol. 2004;24:507-511.
19. Guy W, ed. ECDEU Assessment Manual for Psychopharmacology, revised. DHEW Pub. No. (ADM) 76-338. Rockville, Md: National Institute of Mental Health; 1976.
20. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
21. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
22. Laird NM, Mosteller F. Some statistical methods for combining experimental results. Int J Technol Assess Health Care. 1990;6:5-30.
23. Mosteller F, Colditz GA. Understanding research synthesis (meta-analysis). Annu Rev Public Health. 1996;17:1-23.
24. Sterne JA, Gavaghan D, Egger M. Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol. 2000;53(11):1119-1129.
25. Fieve RR, Goodnick PJ, Peselow ED, et al. Pattern analysis of antidepressant response to fluoxetine. J Clin Psychiatry. 1986;47:560-562.
26. Goodnick PJ, Fieve RR, Peselow ED, et al. Double-blind treatment of major depression with fluoxetine: use of pattern analysis and relation of HAM-D score to CGI change. Psychopharmacol Bull. 1987;23:162-263.
27. Stassen HH, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol. 1993;3(2):127-135.
28. Stassen HH, Angst J, Delini-Stula A. Delayed onset of action of antidepressant drugs? Survey of results of Zurich meta-analyses. Pharmacopsychiatry. 1996;29(3):87-96.
29. Entsuah R, Derivan A, Kikta D. Early onset of antidepressant action of venlafaxine: pattern analysis in intent-to-treat patients. Clin Ther. 1998;20(3):517-526.
30. Storosum JG, Elferink AJ, van Zwieten BJ, et al. Natural course and placebo response in short-term, placebo-controlled studies in major depression: a meta-analysis of published and non-published studies. Pharmacopsychiatry. 2004;37:32-36.
31. Brannan SK, Mallinckrodt CH, Detke MJ, et al. Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res. 2005;39(2):161-172.
32. Kirsch I. Are drug and placebo effects in depression additive? Biol Psychiatry. 2000;47:733-735.
33. Mayberg HS, Brannan SK, Tekell JL, et al. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry. 2000;48(8):830-843.
34. Mayberg HS, Silva JA, Brannan SK, et al. The functional neuroanatomy of the placebo effect. Am J Psychiatry. 2002;159:728-737.
35. Leuchter AF, Cook IA, Witte EA, et al. Changes in brain function of depressed subjects during treatment with placebo. Am J Psychiatry. 2002;159:122-129.
36. Cook IA, Leuchter AF, Morgan M, et al. Early changes in prefrontal activity characterize clinical responders to antidepressants. Neuropsychopharmacology. 2002;27:120-131.
37. Iosifescu DV, Greenwald S, Devlin P, et al. Frontal EEG predicts clinical response to SSRI treatment in MDD. Phoenix, AZ: New Clinical Drug Evaluation Unit National Meeting; 2004.
38. Papakostas GI, Petersen T, Lebowitz BD, et al. The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetine. Int J Neuropsychopharmacol. In press.
39. Papakostas GI, Petersen T, Iosifescu DV, et al. Somatic symptoms as predictors of time to onset of response to fluoxetine in major depressive disorder. J Clin Psychiatry. April 2004;65(4):543-546.
40. Faries D, Herrera J, Rayamajhi J, et al. The responsiveness of the Hamilton Depression Rating Scale. J Psychiatr Res. 2000;34(1):3-10.
41. Khan A, Khan SR, Shankles EB, et al. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials. Int Clin Psychopharmacol. 2002;17(6):281-285.
42. Khan A, Brodhead AE, Kolts RL. Relative sensitivity of the Montgomery-Asberg Depression Rating Scale, the Hamilton Depression Rating Scale and the Clinical Global Impressions Rating Scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol. 2004;19(3):157-160.